In re Direct-to-Consumer Pharmaceutical Advertising

On September 29, 2025, WLF sent a letter to the FDA warning against overreach in the agency’s recent crackdown on direct-to-consumer (DTC) television advertising of prescription drugs. WLF contends that while FDA has authority to combat truly deceptive ads, its broad enforcement actions threaten legitimate commercial speech without clear evidence of widespread violations. WLF calls for balanced regulation that advances public health without suppressing protected speech.